Population Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus Erythematosus

Acharya, C; Magnusson, MO; Vajjah, P; Oliver, R; Zamacona, M

Zamacona, M (通讯作者),UCB Pharm, 208 Bath Rd, Slough SL1 3WE, England.

JOURNAL OF CLINICAL PHARMACOLOGY, 2023; 63 (4): 435

Abstract

Systemic lupus erythematosus (SLE) is a systemic, autoimmune disease characterized by chronic inflammation and organ damage. Dapirolizumab pegol inhib......

Full Text Link